Amgen and Daiichi Sankyo to commercialise biosimilars in Japan
The exclusive agreement includes nine biosimilars in late-stage development
Californian biotechnology firm Amgen and Daiichi Sankyo have signed an exclusive agreement to commercialise nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab.
Under the terms of the agreement, Amgen will be responsible for the development and manufacturing of the biosimilars. Daiichi Sankyo will file for marketing approval and be responsible for distribution and commercialisation in Japan, while Amgen will have a limited right to co-promote the products.
'Amgen is excited to collaborate with Daiichi Sankyo as we seek to drive adoption and build confidence in biosimilars as a means of enhancing patient access to more affordable therapeutic options worldwide,' said Scott Foraker, Vice President and General Manager of Biosimilars at Amgen.
Amgen will retain all additional distribution and commercialisation rights for the biosimilar programmes outside Japan.
Specific financial terms of the agreement have not been disclosed.
